{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:58:30Z","timestamp":1776290310680,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bmcl.2022.128989","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T12:04:55Z","timestamp":1663675495000},"page":"128989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Guanidino quinazolines and pyrimidines promote readthrough of premature termination codons in cells with native nonsense mutations"],"prefix":"10.1016","volume":"76","author":[{"given":"Christie","family":"Morrill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Westley J.","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramil Y.","family":"Baiazitov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane B.","family":"Karloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Choon","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jairo","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tomizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Vazirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen M.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojiao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128989_b0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.bmcl.2022.128989_b0010","doi-asserted-by":"crossref","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"Roy","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128989_b0015","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1007\/s00018-021-03809-7","article-title":"Nonsense suppression therapies in human genetic diseases","volume":"78","author":"Martins-Dias","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmcl.2022.128989_b0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev-genom-091212-153527","article-title":"Therapeutics based on stop codon readthrough","volume":"15","author":"Keeling","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.bmcl.2022.128989_b0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1134\/S0006297920110097","article-title":"A quick guide to small-molecule inhibitors of eukaryotic protein synthesis","volume":"85","author":"Dmitriev","year":"2020","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.bmcl.2022.128989_b0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpdd.914","article-title":"A randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the safety and pharmacokinetics of ELX-02 in healthy subjects","volume":"10","author":"Leubitz","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.bmcl.2022.128989_b0035","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy","volume":"67","author":"Malik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.bmcl.2022.128989_b0040","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/35030019","article-title":"Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics","volume":"407","author":"Carter","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128989_b0045","doi-asserted-by":"crossref","first-page":"10984","DOI":"10.1073\/pnas.1204073109","article-title":"Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin","volume":"109","author":"Matt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128989_b0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1126\/science.1060612","article-title":"Recognition of cognate transfer RNA by the 30S ribosomal subunit","volume":"292","author":"Ogle","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2022.128989_b0055","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0092-8674(02)01086-3","article-title":"Selection of tRNA by the ribosome requires a transition from an open to a closed form","volume":"111","author":"Ogle","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2022.128989_b0060","doi-asserted-by":"crossref","first-page":"E10899","DOI":"10.1073\/pnas.1715501114","article-title":"Aminoglycoside interactions and impacts on the eukaryotic ribosome","volume":"114","author":"Prokhorova","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128989_b0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1261\/rna.060236.116","article-title":"The nucleoside analog clitocine is a potent and efficacious readthrough agent","volume":"23","author":"Friesen","year":"2017","journal-title":"RNA"},{"key":"10.1016\/j.bmcl.2022.128989_b0070","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.0c01489","article-title":"CC-90009: A Cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1 for the treatment of acute myeloid leukemia","volume":"64","author":"Hansen","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128989_b0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128989_b0080","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of small molecule eRF3 degraders on premature termination codon readthrough","volume":"49","author":"Baradaran-Heravi","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2022.128989_b0085","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2022.128989_b0090","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2022.128989_b0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD natural history study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.bmcl.2022.128989_b0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128989_b0105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2217\/cer-2021-0196","article-title":"Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients","volume":"11","author":"McDonald","year":"2022","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.bmcl.2022.128989_b0110","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/cer-2019-0086","article-title":"Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry","volume":"8","author":"Muntoni","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.bmcl.2022.128989_b0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms","volume":"118","author":"Ng","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128989_b0120","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1021\/acsmedchemlett.8b00472","article-title":"New in vitro assay measuring direct interaction of nonsense suppressors with the eukaryotic protein synthesis machinery","volume":"9","author":"Ng","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128989_b0125","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41467-022-30080-6","article-title":"Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination","volume":"13","author":"Huang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2022.128989_b0130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0887-2333(99)00060-0","article-title":"Overview of the final MEIC results: I. The in vitro\u2013in vitro evaluation","volume":"13","author":"Clemedson","year":"1999","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.bmcl.2022.128989_b0135","unstructured":"The measured pKa of 1 was found to be 9.41 by Sirius Analytical using a spectrometric (UV-metric) technique. The sample was titrated in a UV-metric triple titration between pH 2.0\u201312.1 at concentrations of 32\u201325 \u03bcM, under aqueous conditions. No precipitation of the sample from solution was observed, and one pKa, with an average value of 9.41 \u00b1 0.01, was determined from the spectroscopic data collected. An additional potentiometric assay was carried out which confirmed the presence of the pKa reported."},{"issue":"35","key":"10.1016\/j.bmcl.2022.128989_b0140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2122004119","article-title":"2-Guanidino-quinazoline promotes the readthrough of nonsense mutations underlying human genetic diseases","volume":"119","author":"Bidou","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128989_b0145","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1021\/acschemneuro.7b00529","article-title":"Heteroarylguanidines as allosteric modulators of ASIC1a and ASIC3 channels","volume":"9","author":"Alijevic","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.bmcl.2022.128989_b0150","doi-asserted-by":"crossref","first-page":"36059","DOI":"10.1074\/jbc.M112.360487","article-title":"Subtype-specific modulation of acid-sensing ion channel (ASIC) function by 2-guanidine-4-methylquinazoline","volume":"287","author":"Alijevic","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128989_b0155","doi-asserted-by":"crossref","first-page":"e13728","DOI":"10.1111\/nmo.13728","article-title":"Functional involvement of acid-sensing ion channel 3 in the swallowing reflex in rats","volume":"32","author":"Hossain","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bmcl.2022.128989_b0160","doi-asserted-by":"crossref","first-page":"C699","DOI":"10.1152\/ajpcell.00188.2012","article-title":"Structure and activity of the acid-sensing ion channels","volume":"303","author":"Sherwood","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.bmcl.2022.128989_b0165","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/jpet.115.222802","article-title":"Amiloride and GMQ allosteric modulation of the GABA-A rho1 receptor: influences of the intersubunit site","volume":"353","author":"Snell","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmcl.2022.128989_b0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bcp.2018.02.027","article-title":"Multiple regulatory actions of 2-guanidine-4-methylquinazoline (GMQ), an agonist of acid-sensing ion channel type 3, on ionic currents in pituitary GH3 cells and in olfactory sensory (Rolf B1.T) neurons","volume":"151","author":"So","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128989_b0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuropharm.2013.07.018","article-title":"2-Guanidine-4-methylquinazoline acts as a novel competitive antagonist of A type gamma-aminobutyric acid receptors","volume":"75","author":"Xiao","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bmcl.2022.128989_b0180","doi-asserted-by":"crossref","first-page":"21662","DOI":"10.1074\/jbc.M117.814707","article-title":"The nonproton ligand of acid-sensing ion channel 3 activates mollusk-specific FaNaC channels via a mechanism independent of the native FMRFamide peptide","volume":"292","author":"Yang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128989_b0185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2010.09.001","article-title":"A nonproton ligand sensor in the acid-sensing ion channel","volume":"68","author":"Yu","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.bmcl.2022.128989_b0190","doi-asserted-by":"crossref","first-page":"24996","DOI":"10.1074\/jbc.M111.239558","article-title":"Atomic level characterization of the nonproton ligand-sensing domain of ASIC3 channels","volume":"286","author":"Yu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128989_b0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biochi.2016.11.008","article-title":"2-Guanidino-quinazolines as a novel class of translation inhibitors","volume":"133","author":"Komarova Andreyanova","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.bmcl.2022.128989_b0200","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1016\/j.bmcl.2004.07.066","article-title":"Biaryl guanidine inhibitors of in vitro HCV-IRES activity","volume":"14","author":"Jefferson","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128989_b0205","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1021\/acs.jmedchem.7b00285","article-title":"Discovery of novel potent reversible and irreversible myeloperoxidase inhibitors using virtual screening procedure","volume":"60","author":"Soubhye","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128989_b0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/phrs.1996.0092","article-title":"Effects of 2-guanidine-4-methylquinazoline on gastric acid secretion in rats","volume":"34","author":"Pinelli","year":"1996","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2022.128989_b0215","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cell.2018.12.004","article-title":"Small-molecule agonists of Ae. aegypti neuropeptide Y receptor block mosquito biting","volume":"176","author":"Duvall","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2022.128989_b0220","unstructured":"The measured pKas of 19 were found to be 8.16 and 9.95 by Sirius Analytical using a spectrometric (UV-metric) technique. The sample was titrated in a UV-metric triple titration between pH 1.9\u201312.1 at concentrations of 32\u201325 \u03bcM, under aqueous conditions. No precipitation of the sample from solution was observed, and two pKas, with average values of 8.16 \u00b1 0.01 and 9.95 \u00b1 0.01, were determined from the spectroscopic data collected. An additional potentiometric assay was carried out which confirmed the presence of the two pKas reported."},{"key":"10.1016\/j.bmcl.2022.128989_b0225","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/bi011725y","article-title":"Nuclease resistance of oligonucleotides containing the tricyclic cytosine analogues phenoxazine and 9-(2-aminoethoxy)-phenoxazine (\u201cG-clamp\u201d) and origins of their nuclease resistance properties","volume":"41","author":"Maier","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2022.128989_b0230","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/jm00010a010","article-title":"Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase","volume":"38","author":"Wyatt","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128989_b0235","unstructured":"We synthesized this compound (designated as \u201ccompound 57\u201d in reference 40) and found it to be inactive (EC2X > 100 \u00b5M) in the HDQ p53 MSD assay."},{"key":"10.1016\/j.bmcl.2022.128989_b0240","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: a point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:48Z","timestamp":1760773608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22004656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":48,"alternative-id":["S0960894X22004656"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128989","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guanidino quinazolines and pyrimidines promote readthrough of premature termination codons in cells with native nonsense mutations","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128989"}}